Literature DB >> 15196294

Flunarizine effects on oxidative stress in migraine patients.

I Ciancarelli1, M G Tozzi-Ciancarelli, C Di Massimo, C Marini, A Carolei.   

Abstract

Prophylactic activity of flunarizine in migraine is attributed to its antioxidant properties and to the relief of cerebral vasospasm in which nitric oxide (NO) is involved. We investigated the antimigraine activity of flunarizine and its influence on NO and oxidative marker bioavailability in 25 subjects suffering from migraine without aura and in 25 healthy controls. Urinary samples collected before and after treatment with flunarizine (5 mg orally per day for 6 months) were assayed for NO stable metabolites (NOx) and thiobarbituric acid reactive substances (TBARS). Urinary levels of NOx and TBARS were higher in migraine sufferers before treatment than in healthy controls. No differences were observed in NOx levels in migraine sufferers, before and after flunarizine treatment; urinary TBARS levels were decreased after flunarizine treatment (P < 0.05) and remained persistently higher than in healthy controls (P < 0.05). Our results suggest that flunarizine did not prevent NO-mediated vasodilatation, while it proved effective in limiting the oxidative reactions occurring in migraine sufferers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15196294     DOI: 10.1111/j.1468-2982.2003.00705.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  3 in total

1.  Paraoxonase 1 (PON1) polymorphisms and risk for migraine.

Authors:  Elena García-Martín; Carmen Martínez; Mercedes Serrador; Hortensia Alonso-Navarro; Francisco Navacerrada; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  J Neurol       Date:  2010-04-21       Impact factor: 4.849

Review 2.  Comorbid Bipolar Disorder and Migraine: From Mechanisms to Treatment.

Authors:  Jinfeng Duan; Rongmei Yang; Wenwen Lu; Lingfei Zhao; Shaohua Hu; Chenxia Hu
Journal:  Front Psychiatry       Date:  2021-01-11       Impact factor: 4.157

Review 3.  Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.

Authors:  Mirella Russo; Matteo A De Rosa; Dario Calisi; Stefano Consoli; Giacomo Evangelista; Fedele Dono; Matteo Santilli; Alberto Granzotto; Marco Onofrj; Stefano L Sensi
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.